These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 19373021)
1. Microbicide product development. Maguire R Curr Opin HIV AIDS; 2008 Sep; 3(5):554-7. PubMed ID: 19373021 [TBL] [Abstract][Full Text] [Related]
2. Microbicide delivery: formulation technologies and strategies. Romano J; Malcolm RK; Garg S; Rohan LC; Kaptur PE Curr Opin HIV AIDS; 2008 Sep; 3(5):558-66. PubMed ID: 19373022 [TBL] [Abstract][Full Text] [Related]
3. Rectal microbicides. McGowan I; Anton P Curr Opin HIV AIDS; 2008 Sep; 3(5):593-8. PubMed ID: 19373027 [TBL] [Abstract][Full Text] [Related]
4. Microbicide safety and effectiveness: an overview of recent clinical trials. Poynten M; Brown JM; Sovero M; Millwood IY; Kaldor JM Curr Opin HIV AIDS; 2008 Sep; 3(5):574-80. PubMed ID: 19373024 [TBL] [Abstract][Full Text] [Related]
5. Microbicides for the prevention of HIV infection in women: an overview of recent trials. Rosenberg ZF; Nel A; Heyward W; Mitchnick M Curr Opin HIV AIDS; 2006 Nov; 1(6):514-9. PubMed ID: 19372855 [TBL] [Abstract][Full Text] [Related]
6. A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model. Patton DL; Cosgrove Sweeney YT; Paul KJ Sex Transm Dis; 2008 Oct; 35(10):889-97. PubMed ID: 18607310 [TBL] [Abstract][Full Text] [Related]
7. Mathematical models and health economic aspects of microbicides. Wilson DP; Coplan PM Curr Opin HIV AIDS; 2008 Sep; 3(5):587-92. PubMed ID: 19373026 [TBL] [Abstract][Full Text] [Related]
12. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Zolnik BS; Sadrieh N Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437 [TBL] [Abstract][Full Text] [Related]
13. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations. Zhu M; Zhang D; Zhang H; Shyu WC Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287 [TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of hepatocellular carcinoma and molecular therapies. MÃnguez B; Tovar V; Chiang D; Villanueva A; Llovet JM Curr Opin Gastroenterol; 2009 May; 25(3):186-94. PubMed ID: 19387255 [TBL] [Abstract][Full Text] [Related]
15. Microbicide safety/efficacy studies in animals: macaques and small animal models. Veazey RS Curr Opin HIV AIDS; 2008 Sep; 3(5):567-73. PubMed ID: 19373023 [TBL] [Abstract][Full Text] [Related]
17. Regulatory issues in developing new HIV protease inhibitors: risks and benefits. Struble KA; Chan-Tack KM; Soon GG Curr Opin HIV AIDS; 2008 Nov; 3(6):676-80. PubMed ID: 19373041 [TBL] [Abstract][Full Text] [Related]
18. Development of veterinary drug residue controls by the Codex Alimentarius Commission: a review. Ellis RL Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2008 Dec; 25(12):1432-8. PubMed ID: 19680853 [TBL] [Abstract][Full Text] [Related]
19. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321 [TBL] [Abstract][Full Text] [Related]
20. Expanded access to investigational drugs for treatment use. Final rule. Food and Drug Administration, HHS Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]